Identification of SPOP related metabolic pathways in prostate cancer

被引:8
作者
Yan, Min [1 ,2 ,3 ]
Qi, Huan [1 ]
Li, Jia [2 ,3 ]
Ye, Guozhu [2 ,3 ]
Shao, Yaping [2 ,3 ]
Li, Tongming [1 ]
Liu, Jing [1 ]
Piao, Hai-Long [1 ,3 ]
Xu, Guowang [2 ,3 ]
机构
[1] Chinese Acad Sci, Dalian Inst Chem Phys, Sci Res Ctr Translat Med, Dalian 116023, Peoples R China
[2] Chinese Acad Sci, Dalian Inst Chem Phys, CAS Key Lab Separat Sci Analyt Chem, Dalian 116023, Peoples R China
[3] Univ Chinese Acad Sci, Beijing 100049, Peoples R China
关键词
SPOP; metabolism; ANDROGEN RECEPTOR; POTENTIAL BIOMARKER; TCA CYCLE; RNA-SEQ; PROGRESSION; TRANSCRIPTOMICS; DEGRADATION; INTEGRATION; MUTATIONS; UBIQUITINATION;
D O I
10.18632/oncotarget.21460
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Speckle-type POZ protein (SPOP), as a cullin-based E3 ubiquitin ligase, has been identified as one of the most frequently mutated genes in prostate cancer (PCa). However, whether SPOP mutations contribute to metabolic reprogramming in PCa remains unknown. Here, integrated studies of transcriptomics and metabolomics as well as lipidomics were performed in matched PCa tumor (PCT) and adjacent non-tumor (ANT) tissues, followed by correlation analysis of SPOP mutations with altered metabolic pathways in SPOP-mutated PCa patients. Interestingly, transcriptomics profiling showed that all SPOP mutations (with 16.7% frequency, 11/66) occurred at the conserved residues in the substrate binding domain of meprin and TRAF homology (MATH). The results of integrated analysis indicated that three metabolic pathways, including tricarboxylic acid (TCA) cycle, fatty acid metabolism and glycerophospholipid metabolism, exhibited obvious upregulation in SPOP-mutated PCT tissues. Furthermore, both correlation analyses based on integrated data and cBioportal revealed that FH, ELOVL2 and ACADL genes might be involved in SPOP-mutation-related upregulation of these metabolic pathways. Taken together, our study provided new insights in understanding the relationship between metabolic pathways and SPOP mutations in PCa.
引用
收藏
页码:103032 / 103046
页数:15
相关论文
共 50 条
  • [21] Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation
    Wu, Fei
    Dai, Bxiangpeng
    Gan, Wenjian
    Wan, Lixin
    Li, Min
    Mitsiades, Nicholas
    Wei, Wenyi
    Ding, Qiang
    Zhang, Jinfang
    CANCER LETTERS, 2017, 385 : 207 - 214
  • [22] SPOP mutation leads to genomic instability in prostate cancer
    Boysen, Gunther
    Barbieri, Christopher E.
    Prandi, Davide
    Blattner, Mirjam
    Chae, Sung-Suk
    Dahija, Arun
    Nataraj, Srilakshmi
    Huang, Dennis
    Marotz, Clarisse
    Xu, Limei
    Huang, Julie
    Lecca, Paola
    Chhangawala, Sagar
    Liu, Deli
    Zhou, Pengbo
    Sboner, Andrea
    de Bono, Johann S.
    Demichelis, Francesca
    Houvras, Yariv
    Rubin, Mark A.
    ELIFE, 2015, 4
  • [23] Research Progress on The SPOP's Negative Role in The Development of Endometrial Cancer
    Zhuang Hui
    Lin Zi-Han
    Lin Ting
    Cao Xin-Yi
    Jin Xiao-Feng
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2021, 48 (04) : 423 - 433
  • [24] Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer
    Geng, Chuandong
    Rajapakshe, Kimal
    Shah, Shrijal S.
    Shou, John
    Eedunuri, Vijay Kumar
    Foley, Christopher
    Fiskus, Warren
    Rajendran, Mahitha
    Chew, Sue Anne
    Zimmermann, Martin
    Bond, Richard
    He, Bin
    Coarfa, Cristian
    Mitsiades, Nicholas
    CANCER RESEARCH, 2014, 74 (19) : 5631 - 5643
  • [25] The Identification of Potential Biomarkers and Biological Pathways in Prostate Cancer
    Song, Zhengshuai
    Huang, Yu
    Zhao, Ye
    Ruan, Hailong
    Yang, Hongmei
    Cao, Qi
    Liu, Di
    Zhang, Xiaoping
    Chen, Ke
    JOURNAL OF CANCER, 2019, 10 (06): : 1398 - 1408
  • [26] Targeting the 5′-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer
    Popovics, Petra
    Frigo, Daniel E.
    Schally, Andrew V.
    Rick, Ferenc G.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2015, 19 (05) : 617 - 632
  • [27] Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP HIPK2 axis
    Jin, Xiaofeng
    Qing, Shi
    Li, Qian
    Zhuang, Hui
    Shen, Liliang
    Li, Jinhui
    Qi, Honggang
    Lin, Ting
    Lin, Zihan
    Wang, Jian
    Cao, Xinyi
    Yang, Jianye
    Ma, Qi
    Cong, Linghua
    Xi, Yang
    Fang, Shuai
    Meng, Xiaodan
    Gong, Zhaohui
    Ye, Meng
    Wang, Shuyun
    Wang, Chenji
    Gao, Kun
    NUCLEIC ACIDS RESEARCH, 2021, 49 (12) : 6788 - 6803
  • [28] Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis
    Sun, Jian
    Li, Shugen
    Wang, Fei
    Fan, Caibin
    Wang, Jianqing
    BMC MEDICAL GENETICS, 2019, 20 (01)
  • [29] Prognostic value of the SPOP mutant genomic subclass in prostate cancer
    Shoag, Jonathan
    Liu, Deli
    Ma, Xiaoyue
    Oromendia, Clara
    Christos, Paul
    Ballman, Karla
    Angulo, Cynthia
    Cai, Peter Y.
    Gaffney, Christopher
    Klein, Eric
    Karnes, Jeffrey
    Den, Robert B.
    Liu, Yang
    Davicioni, Elai
    Barbieri, Christopher E.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (05) : 418 - 422
  • [30] Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer
    Theurillat, Jean-Philippe P.
    Udeshi, Namrata D.
    Errington, Wesley J.
    Svinkina, Tanya
    Baca, Sylvan C.
    Pop, Marius
    Wild, Peter J.
    Blattner, Mirjam
    Groner, Anna C.
    Rubin, Mark A.
    Moch, Holger
    Prive, Gilbert G.
    Carr, Steven A.
    Garraway, Levi A.
    SCIENCE, 2014, 346 (6205) : 85 - 89